Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $172.00

Merck & Co., Inc. (NYSE:MRK) had its target price hoisted by HSBC from $150.00 to $172.00 in a report issued on Thursday morning,Benzinga reports. HSBC currently has a buy rating on the stock.

A number of other research firms have also weighed in on MRK. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective on the stock in a research report on Wednesday, August 12th. Scotiabank upped their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, June 30th. Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Finally, Morgan Stanley upgraded shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $116.00 to $179.00 in a research note on Thursday, August 20th. Seventeen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $151.32.

Merck & Co., Inc. Stock Down 0.5%

MRK opened at $144.02 on Thursday. The business has a 50 day moving average price of $136.51 and a two-hundred day moving average price of $124.40. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a market cap of $355.33 billion, a PE ratio of 115.22, a P/E/G ratio of 6.26 and a beta of 0.21. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company’s revenue was up 5.1% on a year-over-year basis. During the same period last year, the business posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.4%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Insider Activity at Merck & Co., Inc.

In other news, EVP Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares of the company’s stock, valued at $4,942,755. This represents a 21.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Richard Deluca sold 11,699 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the completion of the transaction, the executive vice president owned 110,167 shares of the company’s stock, valued at $14,501,282.21. This represents a 9.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of hedge funds and other institutional investors have recently modified their holdings of MRK. Brighton Jones LLC raised its stake in shares of Merck & Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after buying an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC increased its holdings in Merck & Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after acquiring an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC increased its holdings in Merck & Co., Inc. by 22.2% during the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after acquiring an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Merck & Co., Inc. by 111.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock worth $53,918,000 after acquiring an additional 359,356 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: HSBC raised its price target for Merck (MRK) from $150 to $172 and maintained a “Buy” rating, implying substantial upside from the recent share price. Benzinga analyst update
• Positive Sentiment: Guggenheim also increased its Merck price target to $170, reinforcing the view that the company’s pipeline, newer medicines and potential cancer-drug combinations can support growth beyond Keytruda. Guggenheim increases Merck price target
• Positive Sentiment: Merck is expanding its development pipeline and commercial portfolio to reduce reliance on Keytruda ahead of its 2028 patent and exclusivity challenges. This provides a longer-term growth narrative, although execution and successful launches remain important. Merck pipeline and new drugs
• Neutral Sentiment: Merck’s stock attracted significant investor attention, but the coverage offers limited new fundamental information. Separately, broader pharmaceutical discussion highlighted manufacturing hurdles for personalized cancer vaccines and risks surrounding confidential industry information. Merck and cancer-vaccine risks
• Negative Sentiment: Investors remain concerned that Merck’s valuation looks demanding relative to its growth rate and to faster-growing peers such as Eli Lilly. Those concerns, combined with the future Keytruda revenue gap, likely contributed to the recent weakness despite higher analyst targets. Merck valuation versus Eli Lilly

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.